Literature DB >> 11413338

Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.

C H Chen1, L Jin, C Zhu, S Holz-Smith, T J Matthews.   

Abstract

Chimpanzees infected with the primary isolate DH012 mount potent neutralizing antibodies. This DH012 neutralizing activity is highly strain specific. Immune sera from guinea pigs immunized with recombinant DH012 gp120 could also neutralize this primary isolate. The neutralizing activity in chimpanzee and guinea pig sera against wild-type DH012 appears to be independent of a linear epitope in the V3 region of gp120. Interestingly, the neutralization escape mutant derived from growing DH012 in the presence of the potent neutralizing chimpanzee serum is at least 50-fold more sensitive than wild-type DH012 to neutralization by guinea pig immune sera. The unusually potent neutralizing activity against the DH012 neutralization-resistant virus is due to the presence of anti-V3 antibodies in guinea pig sera. These results suggested that recombinant gp120 could induce neutralizing antibodies against primary isolate DH012. The V3 of wild-type DH012 is poorly immunogenic in infected chimpanzees and is not accessible to neutralizing V3 antibodies. It is likely that this cryptic V3 region became exposed when the virus escaped the neutralizing activity of the chimpanzee serum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413338      PMCID: PMC114394          DOI: 10.1128/JVI.75.14.6700-6704.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

Authors:  B S Graham; M J McElrath; R I Connor; D H Schwartz; G J Gorse; M C Keefer; M J Mulligan; T J Matthews; S M Wolinsky; D C Montefiori; S H Vermund; J S Lambert; L Corey; R B Belshe; R Dolin; P F Wright; B T Korber; M C Wolff; P E Fast
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

2.  Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.

Authors:  S Beddows; S Louisirirotchanakul; R Cheingsong-Popov; P J Easterbrook; P Simmonds; J Weber
Journal:  J Gen Virol       Date:  1998-01       Impact factor: 3.891

3.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Authors:  M Schreiber; C Wachsmuth; H Müller; S Odemuyiwa; H Schmitz; S Meyer; B Meyer; J Schneider-Mergener
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors.

Authors:  T L Hoffman; E B Stephens; O Narayan; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.

Authors:  M K Gorny; J R Mascola; Z R Israel; T C VanCott; C Williams; P Balfe; C Hioe; S Brodine; S Burda; S Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  1998-02-10       Impact factor: 2.205

6.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  M Thali; C Furman; D D Ho; J Robinson; S Tilley; A Pinter; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

7.  Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Authors:  R B Belshe; G J Gorse; M J Mulligan; T G Evans; M C Keefer; J L Excler; A M Duliege; J Tartaglia; W I Cox; J McNamara; K L Hwang; A Bradney; D Montefiori; K J Weinhold
Journal:  AIDS       Date:  1998-12-24       Impact factor: 4.177

8.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; S Saragosti; H J Fleury; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  9 in total

1.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

4.  Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

Authors:  Kausik Chakraborty; Venuka Durani; Edward Roshan Miranda; Michael Citron; Xiaoping Liang; William Schleif; Joseph G Joyce; Raghavan Varadarajan
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

5.  Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Authors:  Brett Spurrier; Jared M Sampson; Maxim Totrov; Huiguang Li; Timothy O'Neal; Constance Williams; James Robinson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

6.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 7.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

8.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.

Authors:  Ali Azizi; David E Anderson; Masoud Ghorbani; Katrina Gee; Francisco Diaz-Mitoma
Journal:  BMC Immunol       Date:  2006-10-31       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.